Literature DB >> 16483568

Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.

Laurent Reber1, Carla A Da Silva, Nelly Frossard.   

Abstract

Stem cell factor (SCF), the ligand of the c-Kit receptor, is expressed by various structural and inflammatory cells in the airways. Binding of SCF to c-Kit leads to activation of multiple pathways, including phosphatidyl-inositol-3 (PI3)-kinase, phospholipase C (PLC)-gamma, Src kinase, Janus kinase (JAK)/Signal Transducers and Activators of Transcription (STAT) and mitogen activated protein (MAP) kinase pathways. SCF is an important growth factor for mast cells, promoting their generation from CD34+ progenitor cells. In vitro, SCF induces mast cells survival, adhesion to extracellular matrix and degranulation, leading to expression and release of histamine, pro-inflammatory cytokines and chemokines. SCF also induces eosinophil adhesion and activation. SCF is upregulated in inflammatory conditions both in vitro and in vivo, in human and mice. Inhibition of the SCF/c-Kit pathway leads to significant decrease of histamine levels, mast cells and eosinophil infiltration, interleukin (IL)-4 production and airway hyperresponsiveness in vivo. Taken together, these data suggest that SCF/c-Kit may be a potential therapeutic target for the control of mast cell and eosinophil number and activation in inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483568     DOI: 10.1016/j.ejphar.2005.12.067

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  74 in total

Review 1.  Approaches for analyzing the roles of mast cells and their proteases in vivo.

Authors:  Stephen J Galli; Mindy Tsai; Thomas Marichal; Elena Tchougounova; Laurent L Reber; Gunnar Pejler
Journal:  Adv Immunol       Date:  2015-02-07       Impact factor: 3.543

2.  Mast cell function and death in Trypanosoma cruzi infection.

Authors:  Marcelo Meuser-Batista; José Raimundo Corrêa; Vinícius Frias Carvalho; Constança Felícia De Paoli de Carvalho Britto; Otacilio da Cruz Moreira; Marcos Meuser Batista; Maurílio José Soares; Francisco Alves Farias Filho; Patrícia Machado R E Silva; Joseli Lannes-Vieira; Robson Coutinho Silva; Andrea Henriques-Pons
Journal:  Am J Pathol       Date:  2011-08-03       Impact factor: 4.307

Review 3.  Potential effector and immunoregulatory functions of mast cells in mucosal immunity.

Authors:  L L Reber; R Sibilano; K Mukai; S J Galli
Journal:  Mucosal Immunol       Date:  2015-02-11       Impact factor: 7.313

4.  Unusual asthma syndromes and their management.

Authors:  Jaymin B Morjaria; Jack A Kastelik
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

5.  Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.

Authors:  Chao Zhang; Prabha N Ibrahim; Jiazhong Zhang; Elizabeth A Burton; Gaston Habets; Ying Zhang; Ben Powell; Brian L West; Bernice Matusow; Garson Tsang; Rafe Shellooe; Heidi Carias; Hoa Nguyen; Adhirai Marimuthu; Kam Y J Zhang; Angela Oh; Ryan Bremer; Clarence R Hurt; Dean R Artis; Guoxian Wu; Marika Nespi; Wayne Spevak; Paul Lin; Keith Nolop; Peter Hirth; Greg H Tesch; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

Review 6.  The cytokine network in asthma and chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

Review 7.  A survival Kit for pancreatic beta cells: stem cell factor and c-Kit receptor tyrosine kinase.

Authors:  Zhi-Chao Feng; Matthew Riopel; Alex Popell; Rennian Wang
Journal:  Diabetologia       Date:  2015-02-03       Impact factor: 10.122

8.  Eosinophil activation of fibroblasts from chronic allergen-induced disease utilizes stem cell factor for phenotypic changes.

Authors:  Vladislav Dolgachev; Aaron A Berlin; Nicholas W Lukacs
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

9.  Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

Authors:  Jacques Tebib; Xavier Mariette; Pierre Bourgeois; René-Marc Flipo; Philippe Gaudin; Xavier Le Loët; Paul Gineste; Laurent Guy; Colin D Mansfield; Alain Moussy; Patrice Dubreuil; Olivier Hermine; Jean Sibilia
Journal:  Arthritis Res Ther       Date:  2009-06-23       Impact factor: 5.156

10.  Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Authors:  Patrice Dubreuil; Sébastien Letard; Marco Ciufolini; Laurent Gros; Martine Humbert; Nathalie Castéran; Laurence Borge; Bérengère Hajem; Anne Lermet; Wolfgang Sippl; Edwige Voisset; Michel Arock; Christian Auclair; Phillip S Leventhal; Colin D Mansfield; Alain Moussy; Olivier Hermine
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.